Repositorio Digital de la UPF
Publicación
Artículo científico (JournalArticle)
Hotspot propensity across mutational processes
The sparsity of mutations observed across tumours hinders our ability to study mutation rate variability at nucleotide resolution. To circumvent this, here we investigated the propensity of mutational processes to form mutational hotspots as a readout of their mutation rate variability at single base resolution. Mutational signatures 1 and 17 have the highest hotspot propensity (5-78 times higher than other processes). After accounting for trinucleotide mutational probabilities, sequence composition and mutational heterogeneity at 10 Kbp, most (94-95%) signature 17 hotspots remain unexplained, suggesting a significant role of local genomic features. For signature 1, the inclusion of genome-wide distribution of methylated CpG sites into models can explain most (80-100%) of the hotspot propensity. There is an increased hotspot propensity of signature 1 in normal tissues and de novo germline mutations. We demonstrate that hotspot propensity is a useful readout to assess the accuracy of mutation rate models at nucleotide resolution. This new approach and the findings derived from it open up new avenues for a range of somatic and germline studies investigating and modelling mutagenesis., This publication and the underlying study have been made possible partly on the basis of the data that Hartwig Medical Foundation has made available to the study. We acknowledge the technical contributions of Iker Reyes-Salazar and Loris Mularoni to HotspotFinder algorithm and annotations. NL-B acknowledges funding from the European Research Council (consolidator grant 682398) and the European Regional Development Fund/Spanish Ministry of Science, Innovation and Universities—Spanish State Research Agency/DamReMap Project (RTI2018-094095-B-I00) and Fundación Científica Asociación Española Contra el Cáncer (AECC) (GC16173697BIGA). This work has also been supported by the project “Discovering the molecular signatures of cancer PROMotion to INform prevENTion” (PROMINENT) funded by Cancer Research UK (CGCATF-2021/100008), National Cancer Institute (1OT2CA278668-01) and the Spanish Cancer Association, AECC. IRB Barcelona is a recipient of a Severo Ochoa Centre of Excellence Award from the Spanish Ministry of Economy and Competitiveness (MINECO; Government of Spain) and is supported by CERCA (Generalitat de Catalunya). CA-P was supported by “la Caixa” Foundation (ID 100010434) fellowship (LCF/BQ/ES18/11670011).
Proyecto:
EC / H2020 682398
,
ES / 2PE RTI2018-094095-B-I00